Rare complication of ceftriaxone therapy: drug-induced thrombocytopenia (DITP)

BMJ Case Rep. 2021 Sep 6;14(9):e245228. doi: 10.1136/bcr-2021-245228.

Abstract

A 62-year-old woman with a history of end-stage renal disease on haemodialysis, essential hypertension and type 2 diabetes mellitus was diagnosed with sepsis and placed on 600 mg oral linezolid every 12 hours and 1 g intravenous ceftriaxone every 24 hours. Blood cultures grew Streptococcus dysgalactiae, and she was switched to intravenous ceftriaxone 2 g daily. Platelet counts slowly trended down after starting ceftriaxone reaching 5 K/μL on day 12 of treatment. Ceftriaxone was discontinued and heparin-induced thrombocytopaenia was ruled out. She was switched to vancomycin and her platelet count improved. Given the temporal relationship between changing platelet counts and starting and discontinuing ceftriaxone, a diagnosis of drug-induced thrombocytopaenia was made.

Keywords: drugs: infectious diseases; haematology (drugs and medicines); unwanted effects / adverse reactions.

Publication types

  • Case Reports

MeSH terms

  • Ceftriaxone / adverse effects
  • Diabetes Mellitus, Type 2* / drug therapy
  • Female
  • Humans
  • Middle Aged
  • Pharmaceutical Preparations*
  • Streptococcus
  • Thrombocytopenia* / chemically induced

Substances

  • Pharmaceutical Preparations
  • Ceftriaxone

Supplementary concepts

  • Streptococcus dysgalactiae